CA-WIND-RIVER
26.4.2022 12:02:24 CEST | Business Wire | Press release
Wind River® , a global leader in delivering software for intelligent systems, today announced it has been selected by BAE Systems to support technology demonstration work as part of the Tempest future combat air system program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005579/en/
“We are honored be working with BAE Systems,” said Avijit Sinha, chief product officer, Wind River. “The selection of our industry-leading technology demonstrates continuing Wind River leadership in safety-critical real-time software solutions for avionics.”
Wind River software is in use by more than 360 customers over 600 safety programs in more than 100 civilian, military, and space systems, delivering innovative technology that solves real business problems.
BAE Systems will be using the VxWorks 653 platform, a part of Wind River Studio , and associated DO-178C DAL B safety certification evidence packages, and AdaCore GNAT Pro Assurance as part of ongoing technology demonstration project work in support of the program. Wind River Studio is a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems.
The aerospace and defense market has high urgency to build the most complete intelligent systems, according to recent research. True compute on the far edge and the ability to emulate and simulate in real time are two of the most important intelligent systems characteristics for future success. In this industry, the ability to make accurate, quick decisions in high-risk scenarios is critical, and artificial intelligence is becoming an increasingly important investment.1
Team Tempest is a co-funded technology initiative launched by the Royal Air Force Rapid Capabilities Office and U.K. industry partners with the aim of advancing combat air technology. BAE Systems is one of the founding members of Team Tempest.
The Tempest future combat air system will incorporate advanced technical capabilities including AI, which creates opportunities such as the ability to fly manned or unmanned or to use swarming technology to control drones. Tempest is currently in the concept and assessment phase. Initial operating capability is expected in the mid-2030s.
Leveraging a safety-critical platform with COTS safety certification packages can reduce technical program risk. Proven in the most challenging safety-critical applications, VxWorks 653 makes it easier and more cost-effective for technology suppliers to meet the stringent safety certification requirements of EN 50128, IEC 61508, ISO 26262, DO-178C, and ED-12C.
About Wind River
Wind River is a global leader in delivering software for intelligent systems. The company’s technology has been powering the safest, most secure devices in the world since 1981 and is found in billions of products. Wind River offers a comprehensive portfolio, supported by world-class global professional services and support and a broad partner ecosystem. Wind River software and expertise are accelerating digital transformation of mission-critical intelligent systems that will increasingly demand greater compute and AI capabilities while delivering the highest levels of security, safety, and reliability. To learn more, visit Wind River at www.windriver.com .
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005579/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom